My first clinical Trial: 5-ALA & Glioblastoma re-irradiation

For the first time, investor Guy Spier steps outside the world of finance to share a deeply personal conversation—with the doctors who treated him.

 

Recorded at the University Hospital Münster, this discussion with neurosurgeon Dr. Michael Müther and radiation oncologist Dr. Niklas Pepper explores the frontiers of brain cancer treatment, focusing on glioblastoma and a groundbreaking clinical trial combining 5-ALA (Gliolan®) with radiotherapy.

 

Topics covered:

 

What glioblastoma is and why it’s so difficult to treat

The Stupp protocol and why recurrence is common

How 5-ALA fluorescence surgery helps surgeons “see” tumors

The role and evolution of radiotherapy and re-irradiation

A new approach: radiodynamic therapy (5-ALA + radiation)

How clinical trials work (Phase I, dose escalation, safety focus)

Why patient participation is critical to medical progress

 

The conversation also explores the human side of medicine:

 

Should patients deeply engage with their disease—or not?

The role of mindset, movement, and psycho-oncology

How doctors balance research, clinical care, and uncertainty

 

This is a rare, candid look at how modern medicine advances—from lab to patient—and the people behind it.

 

Chapters:

00:00 Introduction

03:10 What is glioblastoma?

06:00 5-ALA and fluorescence-guided surgery

12:37 Radiotherapy explained

17:39 Re-irradiation and treatment evolution

23:50 The new clinical trial (radiodynamic therapy)

35:48 How clinical trials work (Phase I, dose escalation)

45:39 Collaboration in cancer research

53:32 Why Germany leads in this field

59:03 Patient involvement in research

01:01:41 The psychology of disease

01:06:32 Final thoughts

 

Transcript to the whole episode is available here: https://aqfd.docsend.com/view/5gbyupsrddq9ieda

 

Disclaimer:

Nothing contained herein constitutes or should be construed as medical advice. No representations or warranties are made regarding the accuracy or completeness of the information, and it should not be used as a substitute for consultation with a licensed healthcare provider.